Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Nontaxable or Nondeductible items

Nontaxable or Nondeductible items at other companies

Zymeworks logo
ZymeworksZYME
$30.5K-98.8%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpense.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's nontaxable or nondeductible items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's nontaxable or nondeductible items?
ADMA Biologics (ADMA) reported nontaxable or nondeductible items of $699.75K in Q4 2025.
How has ADMA Biologics's nontaxable or nondeductible items changed year-over-year?
ADMA Biologics's nontaxable or nondeductible items decreased by 35.5% year-over-year, from $1.09M to $699.75K.
What is the long-term trend for ADMA Biologics's nontaxable or nondeductible items?
Over 2 years (2023 to 2025), ADMA Biologics's nontaxable or nondeductible items has grown at a 68.7% compound annual growth rate (CAGR), from $983K to $2.8M.
What does nontaxable or nondeductible items mean?
Represents the portion of expenses recognized for financial reporting purposes that are not deductible for income tax calculations. This metric helps investors understand the permanent differences between book income and taxable income, which can impact the company's overall effective tax rate.